Transcription of E 9 Statistical Principles for Clinical Trials
{{id}} {{{paragraph}}}
European Medicines Agency 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 85 75 Fax (44-20) 75 23 70 40 E-mail: EMEA 2006 Reproduction and/or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged September 1998 CPMP/ICH/363/96 ICH Topic E 9 Statistical Principles for Clinical Trials Step 5 NOTE FOR GUIDANCE ON Statistical Principles FOR Clinical Trials (CPMP/ICH/363/96) TRANSMISSION TO CPMP February 1997 RELEASE FOR CONSULTATION February 1997 COMMENTS REQUESTED BEFORE June 1997 FINAL APPROVAL BY CPMP March 1998 DATE FOR COMING INTO OPERATION September 1998 EMEA 2006 2 Statistical Principles FOR Clinical Trials ICH Harmonised Tripartite Guideline Table of Contents I 4 Background and Purpose .. 4 Scope and Direction ..5 II CONSIDERATIONS FOR OVERALL Clinical 6 Trial Context.
should not be taken to imply that other approaches are not appropriate: the use of Bayesian (see Glossary) and other approaches may be considered when the reasons for their use are clear and when the resulting conclusions are sufficiently robust. II CONSIDERATIONS FOR OVERALL CLINICAL DEVELOPMENT 2.1 Trial Context 2.1.1 Development Plan
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}